SI-BONE/$SIBN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About SI-BONE

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Ticker

$SIBN
Primary listing

Industry

Health Care Equipment and Supplies

Employees

349

SI-BONE Metrics

BasicAdvanced
$726M
-
-$0.63
0.93
-

What the Analysts think about SI-BONE

Analyst ratings (Buy, Hold, Sell) for SI-BONE stock.

Bulls say / Bears say

SI-BONE reported a 25% year-over-year increase in Q1 2025 revenue, reaching $47.3 million and surpassing analyst expectations by approximately $2.2 million. (Investing.com)
The company's U.S. revenue growth was particularly robust at 27%, driven by an expanding base of active surgeons and increased sales force productivity. (Investing.com)
Cantor Fitzgerald maintained an 'Overweight' rating for SI-BONE with a $25.00 price target, reflecting confidence in the company's financial health and growth potential. (Investing.com)
SI-BONE reported a net loss of $6.54 million in Q1 2025, indicating ongoing profitability challenges. (TradingView News)
The company's stock is currently trading above its fair value, suggesting potential overvaluation concerns. (Investing.com)
Wellington Management Group LLP reduced its stake in SI-BONE, which could indicate decreased confidence from institutional investors. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

SI-BONE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

SI-BONE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SIBN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs